The Medicare $50 GLP-1 Bridge: A Clinical Guide for Patients Over 65
Starting July 1, 2026, eligible Medicare beneficiaries can access GLP-1 medications for $50/month. Here's everything your doctor should tell you.
The Centers for Medicare & Medicaid Services (CMS) will begin providing eligible Medicare beneficiaries access to GLP-1 medications for weight loss at $50 per month beginning July 1, 2026. The program — called the Medicare GLP-1 Bridge — runs through December 31, 2027, and covers three medications: Foundayo, Wegovy (all formulations), and Zepbound KwikPen.
This is a significant change. Until now, Medicare has not covered GLP-1 medications for obesity. If you're a Medicare beneficiary or caring for someone who is, here's what you need to know.
What Medications Are Covered?
| Medication | Manufacturer | Format | Covered? |
|---|---|---|---|
| Foundayo (orforglipron) | Eli Lilly | Daily oral pill | ✅ All formulations |
| Wegovy (semaglutide) | Novo Nordisk | Weekly injection + daily oral | ✅ All formulations |
| Zepbound (tirzepatide) | Eli Lilly | KwikPen only | ✅ KwikPen only |
| Zepbound single-dose vial/pen | Eli Lilly | Vial or single-dose pen | ❌ Not covered |
| Ozempic/Mounjaro | Various | Various | ❌ Not covered (diabetes indication handled through standard Part D) |
| Compounded GLP-1s | Various | Various | ❌ Not covered |
Who Is Eligible?
To qualify for the Medicare GLP-1 Bridge, you must:
- Be enrolled in a Medicare Part D prescription drug plan (standalone PDP) or a Medicare Advantage plan with prescription drug coverage (MA-PD)
- Meet clinical criteria related to BMI and weight-related health conditions
- Have a prescriber who attests that you meet the prior authorization criteria
- Be using the medication specifically for obesity/weight management (not diabetes)
If you're already taking a GLP-1 for weight loss: You may still qualify. Your prescriber will need to attest that you met the clinical criteria when you first started the medication.
If you're taking a GLP-1 for diabetes: You'll continue to access it through your standard Part D plan, not the Bridge program. The Bridge only covers GLP-1s used for obesity.
Important Limitations You Need to Understand
The $50/month copay sounds straightforward, but there are several caveats your doctor should explain:
The $50 Doesn't Count Toward Your Part D Caps
Under the Bridge program, your $50 monthly copayment does not count toward your Part D deductible or the $2,100 annual out-of-pocket maximum (2026). This means you're paying $50/month on top of your existing drug costs, and it doesn't help you reach catastrophic coverage faster.
Low-Income Subsidy Doesn't Apply
If you receive the Low-Income Subsidy (LIS), also known as Medicare Extra Help, those cost-sharing subsidies do not apply to medications obtained through the Bridge. You'll pay $50/month regardless of your income level. For beneficiaries accustomed to $5–$10 copays, $50 may still be a meaningful financial barrier.
The Program Is Temporary
The Bridge runs from July 1, 2026 through December 31, 2027. After that, it's unclear what happens. The longer-term BALANCE Model was supposed to launch in Medicare Part D in January 2027, but not enough insurance plans signed on. The Bridge was extended from its original 6-month timeline to 18 months as a result. If neither program continues, patients could face a sudden return to full retail pricing.
The Copay Stays Flat Regardless of Dose
This is actually good news: $50 is $50 whether you're on a starting dose or the highest available dose. Unlike cash-pay programs where costs often increase with dose, the Bridge is dose-agnostic.
Bridge vs. Compounded: The Math
For Medicare patients who qualify, the Bridge is almost certainly the better financial deal — but there's a long-term risk. Here's the comparison:
| Option | Monthly Cost | 18-Month Total | What Happens After Dec 2027? |
|---|---|---|---|
| Medicare Bridge | $50 | $900 | Unknown — may face retail pricing ($800-$1,300/mo) |
| Compounded semaglutide | $149–$299 | $2,682–$5,382 | Continues as-is — no program expiration |
If you can afford the $50/month and qualify, start with the Bridge. But consider having a backup plan — either a compounded alternative or a manufacturer savings program — in case the program isn't extended.
Brand-Name GLP-1 Prescriptions
Sesame Care prescribes FDA-approved brand-name medications including those covered under Medicare Bridge.
Sesame Care — From $29/visit →Paid link · Compounded medications are not FDA-approved
How to Enroll
You don't need to enroll separately. If you meet the clinical criteria and have Part D coverage, your prescriber submits a prior authorization through the Bridge's centralized system managed by CMS. Your pharmacy then fills the prescription at the $50 copay.
Talk to your doctor before July 1 to discuss eligibility and get any needed labs or documentation in order so you can access the program as soon as it launches.
What to Ask Your Doctor
- "Do I meet the BMI and comorbidity criteria for the Medicare GLP-1 Bridge?"
- "Which of the three covered medications — Foundayo, Wegovy, or Zepbound KwikPen — is the best fit for me?"
- "What's my backup plan if the Bridge program ends and I still need medication?"
- "Should I start before July 1 with a compounded option, or wait a few weeks for the Bridge?"
Need GLP-1 Access Before July?
GobyMeds offers compounded semaglutide from $99/month — no membership, free shipping, LegitScript certified.
GobyMeds — $99/mo →Paid link · Compounded medications are not FDA-approved
The Bottom Line
The Medicare GLP-1 Bridge is the most significant expansion of weight loss medication access for seniors in decades. At $50/month for brand-name medications, it's an exceptional value — with the caveat that it's temporary and comes with specific limitations. Talk to your doctor now so you're ready when the program launches on July 1.